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1. INTRODUCTION {#clc23294-sec-0006}
===============

Atrial fibrillation (AF) is one of the major causes of stroke,[1](#clc23294-bib-0001){ref-type="ref"} and older age is associated with both higher prevalence of AF[2](#clc23294-bib-0002){ref-type="ref"} and increased incidence of stroke.[3](#clc23294-bib-0003){ref-type="ref"} Many of the Japanese AF patients are of advanced age (≥75 years)[2](#clc23294-bib-0002){ref-type="ref"}, [4](#clc23294-bib-0004){ref-type="ref"}, [5](#clc23294-bib-0005){ref-type="ref"} and thus at high risk of stroke and systemic embolism.[3](#clc23294-bib-0003){ref-type="ref"} The same situation is predicted in the world wide in the near future.[6](#clc23294-bib-0006){ref-type="ref"}, [7](#clc23294-bib-0007){ref-type="ref"}

While warfarin, a vitamin K antagonist, has mainly been used as an oral therapeutic agent in AF for stroke prevention for more than 50 years, its application in elderly patients is not common because of its instability of effect and high incidence rate of serious bleeding.[8](#clc23294-bib-0008){ref-type="ref"}, [9](#clc23294-bib-0009){ref-type="ref"} Several direct oral anticoagulants (DOACs) have been developed as alternatives to warfarin[10](#clc23294-bib-0010){ref-type="ref"} and are currently available worldwide. Apixaban, a direct factor Xa inhibitor, was shown by a worldwide large‐scale randomized clinical trial (ARISTOTLE study) to be effective and safe in stroke prevention for nonvalvular AF patients in comparison with warfarin.[11](#clc23294-bib-0011){ref-type="ref"}

In Asian countries including Japan, AF patients with advanced age often have low body weight and renal dysfunction, being associated with a high risk of bleeding. Thus, many of the elderly AF patients meet the dose reduction criteria configured in each DOAC, although Beers criteria issue a warning on the use of DOACs in these patients.[12](#clc23294-bib-0012){ref-type="ref"} A recent meta‐analysis of the Asian patients with DOACs in the RE‐LY and ENGAGE AF‐TIMI 48 trials revealed that a risk of stroke or systemic embolism was significantly reduced with standard dose compared with low dose while the rates of major bleeding were similar between the two dosing regimens.[13](#clc23294-bib-0013){ref-type="ref"} It should be pointed out that in the global ARISTOTLE study, although the benefits of apixaban were consistently observed in patients aged ≥75 years,[14](#clc23294-bib-0014){ref-type="ref"} a reduced dose (2.5 mg bid) or placebo (ie, warfarin) was administered only to 790 patients (13.9%) among them. Further, in the subanalysis of patients from East Asia (n = 1993),[15](#clc23294-bib-0015){ref-type="ref"} only 255 patients aged ≥75 years were assigned to apixaban. Thus, evidence of apixaban in the elderly AF patients, especially those on reduced dose, is quite limited. On the other hand, DOAC doses prescribed are often inconsistent with each labeling in real‐world clinical practice, and the off‐label reduced dose of apixaban was shown to be associated with a higher risk of stroke than and no significant difference in major bleeding from the on‐label standard dose.[16](#clc23294-bib-0016){ref-type="ref"}

To elucidate the unmet clinical issue on on‐label doses of apixaban especially on‐label reduced dose in the elderly AF patients, we conducted J‐ELD AF Registry, a large‐scale multicenter prospective observational study on the effectiveness and safety of on‐label doses of apixaban in the Japanese nonvalvular AF patients aged ≥75 years.

2. METHODS {#clc23294-sec-0007}
==========

2.1. Study population {#clc23294-sec-0008}
---------------------

The research physician registered patients who satisfied the selection criteria and did not meet any of the exclusion criteria. The selection criteria were AF patients aged ≥75 years without mitral valve stenosis or prosthetic valve who visited the participating facilities after the start of this study and were taking or started taking apixaban. Exclusion criteria were AF patients with (a) a history of hypersensitivity to apixaban, (b) active bleeding symptoms, (c) liver disease with coagulopathy, (d) creatinine clearance \<15 mL/min, and (e) a reduced dose administered although two or more of the dose reduction criteria were not present, which were diagnosed or judged by each investigator. Apixaban was administered according to the package inserts with the reduced dose (2.5 mg bid) when they fulfilled two or more of the following three criteria: ≥80 years of age, body weight \<60 kg, and serum creatinine ≥1.5 mg/dL. Otherwise, the patients received the standard dose (5 mg bid). The registration period was from September 2015 to August 2016, and the observation period of each patient was 1 year.

The paucity of previous data on Japanese elderly AF patients taking apixaban made it difficult to set a rational sample size. As this was not a comparative study with warfarin but an exploratory study, to clarify the effectiveness and safety of apixaban in elderly AF patients, the sample size was set to 3000 patients considering the feasibility of the analysis.

2.2. Ethics and informed consent {#clc23294-sec-0009}
--------------------------------

The study design of J‐ELD AF Registry[17](#clc23294-bib-0017){ref-type="ref"} was published previously (UMIN Clinical Trials Registry: UMIN000017895). The study protocol was approved by the ethics committee of each research facility where the study was conducted. Prior to the registration of patients, the research physician explained the study to the patient using explanatory and agreement documents, and obtained written consent. If the patient withdrew consent during the participation period (observation period) of this study, the study for the patient was discontinued and all existing data collected from the patient were discarded.

2.3. Data acquisition {#clc23294-sec-0010}
---------------------

In this study, observation and examination items prescribed in the clinical study implementation plan were collected using an Electronic Data Capture (EDC) system. We collected data on consent acquisition date, age, sex, body weight, underlying diseases (heart failure, hypertension, diabetes, a history of cerebral infarction or transient ischemic attacks \[TIAs\], myocardial infarction \[MI\], peripheral artery disease, a history of hospitalization due to bleeding requiring hospitalization, etc.), apixaban dose and its start date, coadministration of antiplatelet drugs, and so on, at the time of registration. The estimated glomerular filtration rate (eGFR) was estimated using the Modification of Diet in Renal Disease study equation: 194 × serum creatinine^‐1.094^ × age^‐0.287^ × 0.739 (if female).[18](#clc23294-bib-0018){ref-type="ref"} Creatinine clearance was estimated using the Cockcroft‐Gault formulae.[19](#clc23294-bib-0019){ref-type="ref"}

The events were (a) diagnosed stroke with head computed tomography or magnetic resonance imaging with clinical symptoms, (b) systemic embolism confirmed by diagnostic imaging with clinical symptoms, (c) bleeding requiring hospitalization, (d) total death, and (e) cardiovascular death. Patient data were imported into the EDC in an anonymized and unidentifiable state, and were managed by an external third party entrusted by the Cardiovascular Institute Academic Research Organization (CVI ARO).

2.4. Evaluation and statistical analysis {#clc23294-sec-0011}
----------------------------------------

The primary endpoints for determining effectiveness and safety were stroke or systemic embolism and bleeding requiring hospitalization, respectively. Secondary endpoints were total death and cardiovascular death. We first calculated the event incidences and their 95% confidence interval (95% CI) by the person‐years method. Moreover, the cumulative event incidences were displayed by the Kaplan‐Meier method, and the differences between groups were tested by the logrank test. Univariate and multivariate models by the Cox regression analysis were then identified. In the multivariate model, apixaban dose was forcibly introduced and then adjusted by the stepwise method with factors composing relevant thromboembolic or bleeding risk scores (ie, CHADS~2~, CHA~2~DS~2~‐VASc, and HAS‐BLED scores): age (≥85 years), male sex, heart failure, hypertension, diabetes mellitus, history of cerebral infarction or TIA, history of MI or peripheral artery disease, history of bleeding requiring hospitalization, liver dysfunction, renal dysfunction (eGFR \<45 mL/min/m^2^), habitual drinking, and use of antiplatelet drugs. Among them, the components of age and renal dysfunction were different from original definition of each risk score, but we modified them to secure the statistical power for the adjustment. In all analyses, two‐sided *P* \< .05 was taken to indicate statistical significance. Statistical analyses were performed using SAS Ver. 9.4 (SAS Institute Inc., Cary, North Carolina).

3. RESULTS {#clc23294-sec-0012}
==========

Of 3066 patients registered from 110 nationwide participating institutions (Table [S1](#clc23294-supInfo-0001){ref-type="supplementary-material"}), 35 were excluded (withdrawal of consent, n = 9; dropout, n = 26), and the remaining 3031 patients (average age, 81.7 years; female, 48.2%) were included in the analyses.

3.1. Patient characteristics {#clc23294-sec-0013}
----------------------------

Table [1](#clc23294-tbl-0001){ref-type="table"} shows the baseline characteristics of the study population. Of 3031 patients, a standard dose was administered in 1284 (42.4%), while a reduced dose in the remaining 1747 (57.6%). The reduced dose group had a higher age by 5.6 years, higher prevalence of female gender by 1.6 times, lower body weight by 12.1 kg, and lower estimated creatinine clearance by 18.6 mL/min than the standard dose group. The prevalence of pre‐existing heart failure and cerebral infarction or TIAs was also significantly higher in the reduced dose group. The CHADS~2~ scores were 2.8 ± 1.1 and 2.9 ± 1.1 in the standard and reduced dose groups, respectively. Although small, the difference between the two groups was significant (*P* \< .001). Similarly, the CHA~2~DS~2~‐VASc scores were 4.2 ± 1.2 and 4.6 ± 1.2 in the standard and reduced dose groups, respectively (*P* \< .001). The HAS‐BLED scores were 2.5 ± 0.8 and 2.4 ± 0.8 in the standard and reduced dose groups, respectively (*P* \< .001).

###### 

Patient demographics

                                                         Total          Standard dose (5 mg bid)   Reduced dose (2.5 mg bid)   
  ------------------------------------------------------ -------------- -------------------------- --------------------------- --------
  Gender                                                                                                                       \<.001
  Male, n (%)                                            1570 (51.8)    855 (66.6)                 715 (40.9)                  
  Female, n (%)                                          1461 (48.2)    429 (33.4)                 1032 (59.1)                 
  Age, years                                             81.7 ± 4.6     78.5 ± 3.2                 84.1 ± 4.1                  \<.001
  Age ≥ 85 y, n (%)                                      843 (27.8)     94 (7.3)                   749 (42.9)                  \<.001
  Body weight, kg                                        56.3 ± 11.2    63.3 ± 10.5                51.2 ± 8.6                  \<.001
  Systolic blood pressure, mmHg                          127.2 ± 17.4   128.8 ± 16.3               126.1 ± 18.0                \<.001
  Diastolic blood pressure, mmHg                         70.7 ± 12.3    72.8 ± 12.0                69.2 ± 12.3                 \<.001
  Pulse rate, beats/min                                  74.1 ± 15.0    73.9 ± 15.5                74.3 ± 14.5                 .479
  Serum creatinine, mg/dL                                1.0 ± 0.3      0.9 ± 0.2                  1.0 ± 0.4                   \<.001
  Creatinine clearance, mL/min                           46.6 ± 16.2    57.3 ± 14.1                38.7 ± 12.8                 \<.001
  Atrial fibrillation types, n (%)                                                                                             .113
  Paroxysmal                                             1023 (33.8)    407 (31.7)                 616 (35.3)                  
  Persistent                                             488 (16.1)     225 (17.5)                 263 (15.1)                  
  Permanent                                              1488 (49.1)    637 (49.6)                 851 (48.7)                  
  Unknown                                                32 (1.1)       15 (1.2)                   17 (1.0)                    
  EHRA score, n (%)                                                                                                            .144
  1                                                      1656 (56.8)    725 (56.5)                 931 (53.3)                  
  2                                                      1059 (36.3)    433 (33.7)                 626 (35.8)                  
  3                                                      174 (6.0)      64 (5.0)                   110 (6.3)                   
  4                                                      27 (0.9)       9 (0.7)                    18 (1.0)                    
  Heart failure, n (%)                                   1071 (35.3)    338 (26.3)                 733 (42.0)                  \<.001
  Hypertension, n (%)                                    2720 (89.7)    1168 (91.0)                1552 (88.8)                 .056
  Diabetes mellitus, n (%)                               702 (23.2)     336 (26.2)                 366 (21.0)                  \<.001
  History of cerebral infarction/TIA n (%)               532 (17.6)     205 (16.0)                 327 (18.7)                  .049
  History of MI/peripheral artery disease, n (%)         287 (9.5)      120 (9.3)                  167 (9.6)                   .843
  History of bleeding requiring hospitalization, n (%)   54 (1.8)       21 (1.6)                   33 (1.9)                    .678
  Liver dysfunction, n (%)                               29 (1.0)       13 (1.0)                   16 (0.9)                    .851
  eGFR \<45 mL/min/1.73m^2^, n (%)                       916 (30.2)     220 (17.1)                 696 (39.8)                  \<.001
  Habitual drinking, n (%)                               407 (13.4)     259 (20.2)                 148 (8.5)                   \<.001
                                                                                                                               
  Antiplatelet drugs, n (%)                              558 (18.4)     241 (18.8)                 317 (18.1)                  .670
  CHADS~2~ score                                                                                                               
  Consecutive                                            2.8 ± 1.1      2.8 ± 1.1                  2.9 ± 1.1                   \<.001
  Category, n (%)                                                                                                              \<.001
  0                                                      0 (0.0)        0 (0.0)                    0 (0.0)                     
  1                                                      164 (5.4)      72 (5.6)                   92 (5.3)                    
  2                                                      1187 (39.2)    561 (43.7)                 626 (35.8)                  
  3                                                      974 (32.1)     370 (28.8)                 604 (34.6)                  
  4                                                      451 (14.9)     193 (15.0)                 258 (14.8)                  
  5                                                      206 (6.8)      68 (5.3)                   138 (7.9)                   
  6                                                      49 (1.6)       20 (1.6)                   29 (1.7)                    
  CHA~2~DS~2~‐VASc score                                                                                                       
  Consecutive                                            4.4 ± 1.2      4.2 ± 1.2                  4.6 ± 1.2                   \<.001
  Category, n (%)                                                                                                              \<.001
  0                                                      0 (0.0)        0 (0.0)                    0 (0.0)                     
  1                                                      0 (0.0)        0 (0.0)                    0 (0.0)                     
  2                                                      87 (2.9)       48 (5.0)                   39 (3.4)                    
  3                                                      612 (20.3)     359 (37.6)                 253 (22.0)                  
  4                                                      1065 (35.3)    426 (44.7)                 639 (55.5)                  
  5                                                      729 (24.1)     275 (28.8)                 454 (39.4)                  
  6                                                      357 (11.8)     125 (13.1)                 232 (20.2)                  
  7                                                      143 (4.7)      42 (4.4)                   101 (8.8)                   
  8                                                      33 (1.1)       8 (0.8)                    25 (2.2)                    
  9                                                      5 (0.2)        1 (0.1)                    4 (0.3)                     
  HAS‐BLED score                                                                                                               
  Consecutive                                            2.4 ± 0.8      2.5 ± 0.8                  2.4 ± 0.8                   \<.001
  Category, n (%)                                                                                                              .005
  0                                                      0 (0.0)        0 (0.0)                    0 (0.0)                     
  1                                                      198 (6.6)      73 (7.7)                   125 (10.9)                  
  2                                                      1656 (54.8)    665 (69.7)                 991 (86.1)                  
  3                                                      901 (29.8)     407 (42.7)                 494 (42.9)                  
  4                                                      253 (8.4)      128 (13.4)                 125 (10.9)                  
  5                                                      22 (0.7)       11 (1.2)                   11 (1.0)                    
  6                                                      1 (0.0)        0 (0.0)                    1 (0.1)                     
  7                                                      0 (0.0)        0 (0.0)                    0 (0.0)                     
  8                                                      0 (0.0)        0 (0.0)                    0 (0.0)                     

Abbreviations: eGFR, estimated glomerular filtration rate; EHRA, European Heart Rhythm Association; MI, myocardial infarction; TIA, transient ischemic attack.

3.2. Primary endpoints {#clc23294-sec-0014}
----------------------

### 3.2.1. Stroke or systemic embolism {#clc23294-sec-0015}

The incidence rate of stroke or systemic embolism was 1.67 per 100 person‐years (95% CI: 1.08‐2.58) and 1.56 per 100 person‐years (95% CI: 1.05‐2.30) in the standard and reduced dose group, respectively (logrank test, *P* = .813; Table [2](#clc23294-tbl-0002){ref-type="table"}, Figure [1](#clc23294-fig-0001){ref-type="fig"}).

###### 

Event incidence rate

                                       Events   Person‐years   Event rate (95% CI) (/100 person‐years)
  ------------------------------------ -------- -------------- -----------------------------------------
  Stroke or systemic embolism                                  
  Total                                45       2805           1.60 (1.20‐2.15)
  Standard dose                        20       1197           1.67 (1.08‐2.58)
  Reduced dose                         25       1608           1.56 (1.05‐2.30)
                                                               
  Bleeding requiring hospitalization                           
  Total                                53       2801           1.89 (1.45‐2.47)
  Standard dose                        17       1198           1.42 (0.89‐2.27)
  Reduced dose                         36       1602           2.25 (1.62‐3.11)
                                                               
  Total death                                                  
  Total                                89       2821           3.16 (2.56‐3.88)
  Standard dose                        17       1205           1.41 (0.88‐2.26)
  Reduced dose                         72       1615           4.46 (3.54‐5.61)
                                                               
  Cardiovascular death                                         
  Total                                27       2821           0.96 (0.66‐1.39)
  Standard dose                        *5*      1205           0.41 (0.18‐0.97)
  Reduced dose                         22       1615           1.36 (0.90‐2.06)

Abbreviations: CI, confidence interval.

![Cumulative incidences shown by Kaplan‐Meier Method. A, Stroke or systemic embolism. B, Bleeding requiring hospitalization. C, Total death. D, Cardiovascular death](CLC-43-251-g001){#clc23294-fig-0001}

In the univariate models of Cox regression analysis, reduced apixaban dose was not significantly associated with stroke or systemic embolism (hazard ratio \[HR\] 0.93, 95% CI: 0.52‐1.68, *P* = 0.813). In the multivariate model, HR of reduced apixaban dose was 0.91 (95% CI: 0.50‐1.63, *P* = 0.746), and history of cerebral infarction or TIA (HR 2.32, 95% CI: 1.25‐4.32, *P* = 0.008) and history of bleeding requiring hospitalization (HR 4.01, 95% CI: 1.24‐12.94, *P* = 0.020) were independently associated with stroke or systemic embolism (Table [3](#clc23294-tbl-0003){ref-type="table"}).

###### 

Cox hazard ratio of the stroke or systemic embolism, and the bleeding requiring hospitalization

                                                  Univariate model    Multivariate model                       
  ----------------------------------------------- ------------------- -------------------- ------------------- -------
  The stroke or systemic embolism                                                                              
  Reduced (vs standard) dose                      0.93 (0.52‐1.68)    0.813                0.91 (0.50‐1.63)    0.746
  Age ≥ 85 years                                  1.33 (0.71‐2.46)    0.372                                    
  Male sex                                        1.18 (0.65‐2.13)    0.591                                    
  Heart failure                                   0.53 (0.26‐1.06)    0.073                                    
  Hypertension                                    1.63 (0.51‐5.27)    0.412                                    
  Diabetes mellitus                               1.07 (0.54‐2.10)    0.855                                    
  History of cerebral infarction/TIA              2.33 (1.26‐4.34)    0.007                2.32 (1.25‐4.32)    0.008
  History of MI/PAD                               0.95 (0.34‐2.67)    0.930                                    
  History of bleeding requiring Hospitalization   4.11 (1.27‐13.27)   0.018                4.01 (1.24‐12.94)   0.020
  Liver dysfunction                               1.16 (0.54‐2.49)    0.706                                    
  eGFR \<45 mL/min/m^2^                           0.85 (0.44‐1.64)    0.623                                    
  Habitual drinking                               1.87 (0.92‐3.77)    0.082                                    
  Antiplatelet drugs                              1.14 (0.55‐2.36)    0.727                                    
  The bleeding requiring hospitalization                                                                       
  Reduced (vs standard) dose                      1.54 (0.86‐2.75)    0.144                1.33 (0.73‐2.42)    0.348
  Age ≥ 85 years                                  1.53 (0.87‐2.68)    0.142                                    
  Male sex                                        1.01 (0.59‐1.75)    0.965                                    
  Heart failure                                   1.06 (0.61‐1.87)    0.827                                    
  Hypertension                                    0.89 (0.38‐2.08)    0.785                                    
  Diabetes mellitus                               0.89 (0.45‐1.72)    0.719                                    
  History of cerebral infarction/TIA              0.97 (0.47‐1.98)    0.926                                    
  History of MI/PAD                               2.06 (1.00‐4.22)    0.049                                    
  History of bleeding requiring hospitalization   3.51 (1.09‐11.25)   0.035                3.81 (1.18‐12.23)   0.025
  Liver dysfunction                               1.44 (0.74‐2.80)    0.283                                    
  eGFR \<45 mL/min/m^2^                           2.00 (1.16‐3.45)    0.012                1.80 (1.02‐3.17)    0.042
  Habitual drinking                               1.00 (0.45‐2.23)    0.991                                    
  Antiplatelet drugs                              2.02 (1.12‐3.65)    0.019                1.98 (1.09‐3.57)    0.024

Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; PAD, peripheral artery disease; TIA, transient ischemic attack.

### 3.2.2. Bleeding requiring hospitalization {#clc23294-sec-0016}

The incidence of bleeding requiring hospitalization was 1.42 per 100 person‐years (95% CI: 0.89‐2.27) and 2.25 per 100 person‐years (95% CI: 1.62‐3.11) in the standard and reduced dose groups, respectively (logrank test, *P* = 0.141; Table [2](#clc23294-tbl-0002){ref-type="table"} and Figure [1](#clc23294-fig-0001){ref-type="fig"}).

In the univariate models of Cox regression analysis for bleeding requiring hospitalization, reduced apixaban dose was not significantly associated with bleeding requiring hospitalization (HR 1.54, 95% CI: 0.86‐2.75, *P* = 0.144). In the multivariate model, HR of reduced apixaban dose was 1.33 (95% CI: 0.73‐2.42, *P* = 0.348), and history of bleeding requiring hospitalization (HR 3.81, 95% CI: 1.18‐12.23, *P* = 0.025), reduced renal function (eGFR \<45 mL/min/1.73^2^) (HR 1.80, 95%CI: 1.02‐3.17, *P* = 0.042), and co‐administration of antiplatelet drug (HR 1.98, 95% CI: 1.09‐3.57, *P* = 0.024) were independently associated with bleeding requiring hospitalization (Table [3](#clc23294-tbl-0003){ref-type="table"}).

3.3. Secondary endpoints {#clc23294-sec-0017}
------------------------

### 3.3.1. Total death {#clc23294-sec-0018}

The incidences of total death were 1.41 per 100 person‐years (95% CI: 0.88‐2.26) and 4.46 per 100 person‐years (95% CI: 3.54‐5.61) in the standard and reduced dose groups, respectively (logrank test, *P* \< 0.001; Table [2](#clc23294-tbl-0002){ref-type="table"}, Figure [1](#clc23294-fig-0001){ref-type="fig"}).

In the univariate models of Cox regression analysis, reduced apixaban dose was significantly associated with total death (HR 3.17, 95% CI: 1.87‐5.38, *P* \< 0.001), and the association was independent in the multivariate model (HR 3.19, 95% CI: 1.86‐5.48, *P* \< 0.001). Besides the apixaban dose, heart failure (HR 2.48, 95% CI: 1.61‐3.81, *P* \< 0.001), male sex (HR 1.92, 95% CI: 1.23‐2.94, *P* = 0.004), and co‐administration of antiplatelet drugs (HR 1.63, 95% CI 1.02‐2.59, *P* = 0.040) were independently associated with total death in the multivariate model (Table [S2](#clc23294-supitem-0002){ref-type="supplementary-material"}).

### 3.3.2. Cardiovascular death {#clc23294-sec-0019}

The incidences of cardiovascular death were 0.41 per 100 person‐years (95% CI: 0.18‐0.97) and 1.36 per 100 person‐years (95% CI: 0.90‐2.06) in the standard and reduced dose groups, respectively (logrank test, *P* = .011; Table [2](#clc23294-tbl-0002){ref-type="table"}, Figure [1](#clc23294-fig-0001){ref-type="fig"}).

In the univariate models of Cox regression analysis, reduced apixaban dose was significantly associated with cardiovascular death (HR 3.30, 95% CI: 1.25‐8.71, *P* \< .001), and the association was independent in the multivariate model (HR 3.22, 95% CI: 1.20‐8.67, *P* = .021). Besides the apixaban dose, heart failure (HR 4.65, 95% CI: 1.95‐11.09, *P* = .001), and male sex (HR 2.94, 95% CI: 1.30‐6.67, *P* = .010) were independently associated with cardiovascular death in the multivariate model.

4. DISCUSSION {#clc23294-sec-0020}
=============

In this study, on‐label doses of apixaban were administered to the Japanese elderly AF patients aged ≥75 years, and one‐year outcomes were prospectively analyzed for standard and reduced dose groups. We found that the incidences of stroke or systemic embolism and bleeding requiring hospitalization after apixaban were both low and similar between the two dose groups. The predictors for stroke or systemic embolism were histories of cerebral infarction/TIAs and bleeding requiring hospitalization, while those for major bleeding were history of bleeding requiring hospitalization, reduced renal dysfunction (eGFR \<45 mL/min/m^2^) and coadministration of antiplatelet drug. Importantly, a reduced dose (2.5 mg bid) was not associated with increased risk of either stroke or major bleeding, but was with increased mortality due to higher age and more comorbidities in this group.

4.1. Incidences of outcomes in elderly patients under on‐label doses of apixaban {#clc23294-sec-0021}
--------------------------------------------------------------------------------

In this J‐ELD AF Registry, we prospectively enrolled and analyzed 3031 patients with an average age of 81.7 years, and included more elderly AF patients than in previous studies.[8](#clc23294-bib-0008){ref-type="ref"}, [11](#clc23294-bib-0011){ref-type="ref"}, [20](#clc23294-bib-0020){ref-type="ref"}, [21](#clc23294-bib-0021){ref-type="ref"}, [22](#clc23294-bib-0022){ref-type="ref"}, [23](#clc23294-bib-0023){ref-type="ref"} The results showed that the event rates of stroke or systemic embolism and bleeding requiring hospitalization were 1.60 and 1.89 per 100 person‐years, respectively. A global ARISTOTLE study showed that the event rate of stroke or systemic embolism and that of major bleeding by International Society on Thrombosis and Haemostasis (ISTH) definition were 1.6%/year and 3.3%/year, respectively, in the patient group assigned to apixaban and with age ≥75 years.[11](#clc23294-bib-0011){ref-type="ref"} Similar rates for stroke and systemic embolism to and lower rates for bleeding than those in ARISTOTLE study were observed in this study.

In Fushimi AF Registry conducted in Japan, the rates of stroke or systemic embolism and ISTH major bleeding for all patients (mean age, 73.9 years; female, 40.3%; 53.1% anticoagulated) were 2.7 and 1.5 per 100 person‐years, respectively.[20](#clc23294-bib-0020){ref-type="ref"} Those for patients aged ≥85 years (41.3% anticoagulated) were 5.1 and 2.0 per 100 person‐years, respectively.[3](#clc23294-bib-0003){ref-type="ref"} In SAKURA‐AF Registry conducted in Japan, 438 patients received apixaban (mean age, 73.2 years; female, 35.8%), and the rates of stroke or systemic embolism and major bleeding were 0.7 and 0.7 at 1 year, and 3.5 and 3.3 at 2 years.[24](#clc23294-bib-0024){ref-type="ref"} Although the events rates should differ by the patient characteristics of each cohort, our results provide features of Japanese elderly AF patients anticoagulated by on‐label dose of apixaban.

4.2. Comparison of outcomes in on‐label standard and reduced doses of apixaban {#clc23294-sec-0022}
------------------------------------------------------------------------------

The patients in the reduced dose group in this study were older, included more females, and had lower body weight and lower estimated creatinine clearance in comparison to the standard dose group. Further, significantly higher rates of previous histories of heart failure and cerebral infarction or TIAs were noted in the reduced dose group. Thus, the reduced dose group in the present study was considered to consist of patients with higher risks of stroke compared with previous studies.[8](#clc23294-bib-0008){ref-type="ref"}, [11](#clc23294-bib-0011){ref-type="ref"}, [20](#clc23294-bib-0020){ref-type="ref"}, [21](#clc23294-bib-0021){ref-type="ref"}, [22](#clc23294-bib-0022){ref-type="ref"}, [23](#clc23294-bib-0023){ref-type="ref"} Meanwhile, the HAS‐BLED score was slightly but significantly lower in the reduced dose group than in the standard dose group.

Despite their estimated higher risk in the reduced dose group, no significant differences in the primary event rates were observed between standard and reduced dose groups. This was consistent with the results of patients aged ≥75 years in the global ARISTOTLE study for standard and reduced dose groups: 1.54%/year and 1.65%/year, respectively, for stroke or systemic embolism, and 3.21%/year and 3.29%/year for ISTH major bleeding, respectively.[14](#clc23294-bib-0014){ref-type="ref"} On the other hand, this study showed that the reduced dose was significantly associated with higher total death and cardiovascular death. This can be explained by the facts that the reduced dose group had higher age, lower body weight, lower renal function, and higher prevalence of heart failure than the standard dose group, all of which were considered to be associated with higher mortality.

5. CLINICAL IMPLICATIONS {#clc23294-sec-0023}
========================

The Asian elderly AF patients often have low body weight and low renal function compared with the Western patients,[15](#clc23294-bib-0015){ref-type="ref"} and therefore, many of them receive a reduced‐dose apixaban. This study revealed the effectiveness and safety of the on‐label reduced dose apixaban in \>1700 elderly AF patients, supporting the conclusions shown in the ARISTOTLE subanalysis for the elderly patients.[14](#clc23294-bib-0014){ref-type="ref"} Since underdosing of apixaban is associated with a higher stroke risk but a similar major bleeding risk,[16](#clc23294-bib-0016){ref-type="ref"} it would be important to follow the labeling in the elderly AF patients.

6. LIMITATIONS {#clc23294-sec-0024}
==============

There were several limitations in the present study. First, this J‐ELD AF Registry was a prospective, single‐arm, observational study, and therefore, there was no control arm with which the effect of apixaban was compared. Second, there may have been selection bias for patients. Research physicians might not have enrolled patients at a very high risk who were not suitable for long‐term on‐label doses of apixaban. Third, this study consisted of patients with relatively well‐managed AF since they could be fully followed up by medical institution with cardiovascular specialists on staff. Thus, the patients\' health conditions and medical environments may have affected the event incidence rates. Fourth, the observation period was limited to 1 year, and therefore, the results could not be extrapolated to a long‐term clinical course of more than 1 year. Fifth, the outcome events were reported by each participating center, and central adjudication was not performed. However, by simplifying the definition of the stroke and bleeding events, we believe the variation in the local diagnosis between participating centers was modest. Sixth, the status of adherence, discontinuation, or change to other anticoagulants, which would affect the patient outcomes, was not recorded in the present study. Lastly, this study does not include patients taking off‐label underdose, which is common in real‐world clinical practice. The benefit of underdose DOAC is an important matter of debate, but this was not the scope of the present study.

7. CONCLUSIONS {#clc23294-sec-0025}
==============

We examined the clinical course of the Japanese nonvalvular AF patients with advanced age in whom on‐label doses of apixaban were administered. The incidences of stroke or systemic embolism and bleeding requiring hospitalization were relatively low and were similar between the standard and reduced dose groups. The incidences of total death and cardiovascular death were both significantly higher in the reduced dose group due to the coexisting higher risks in this group.
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